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ABSTRACT 
The presence of missense mutations detected during genetic testing makes it difficult to 
classify their pathogenic effect. It is possible that the predicted amino acid change affects 
protein function; however, it is also possible that a missense mutation does not act at the 
protein level but rather at the nucleotide level by interfering with the correct assembly of the 
pre-mRNA splicing machinery. In this chapter we describe that short 6 to 9 nucleotides-
containing sequence motifs act as exonic splicing regulatory elements. They are specifically 
recognized by corresponding splicing factors, which then assist in the recognition of the 
conserved splice site motifs by the spliceosome. Many examples show that a point mutation 
in these exonic splicing regulatory elements is sufficient to change splicing factor binding, 
which impairs inclusion of an exon during the splicing reaction. Thus, the molecular 
consequence of a missense mutation can be exon skipping and thus cause a frameshift in the 
messenger RNA that results in a premature stop codon and loss of function of the affected 
allele. Although several bioinformatic tools exist to predict splicing factor binding to mRNA, 
this effect of a missense mutation on splicing cannot yet be accurately predicted by sequence 
analysis alone. In order to determine whether a missense mutation has a deleterious effect on 
splicing of the corresponding mRNA, experimental analysis with either patient RNA or 
splicing reporter minigenes is required. 
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INTRODUCTION 
Genetic diseases are characterized by the presence of mutations that inactivate single 
genes. The sequence analysis of the corresponding candidate disease genes allows 
confirmation of diagnosis or realization of genetic testing in family members. Whenever 
sequence variants are found during routine genetic testing, they are classified as pathogenic 
mutations if they either (a) result in the introduction of a stop codon that truncates the protein 
(for example, an amino acid alteration to a stop codon or as consequence of a frameshift), or 
(b) affect an invariant splice junction consensus sequence, or (c) were previously reported as 
pathogenic in the literature based on supporting functional data (Cotton and Scriver 1999).  
These criteria are not fulfilled if a missense mutation is detected. It is possible that the 
predicted amino acid change affects protein function, but this requires experimental 
confirmation using biochemical or cellular activity assays. Increasing evidence over the last 
decade has, however, demonstrated that many missense mutations rather act at the nucleotide 
level. This is due to the complexity of the pre-mRNA splicing process, which separates the 
coding information of the exons from the more abundant non-coding sequences in the introns. 
This process not only relies on consensus sequences at the intron/exon junction but also 
requires additional splicing regulatory elements in their vicinity, including the exon 
sequences. Many examples have shown that a single nucleotide change in an exon can 
interfere with the correct assembly of the splicing machinery and lead to either complete 
skipping of the exon, retention of an intron, or the introduction of a new splice site within an 
exon or intron. In consequence, even translationally silent sequence variations now need to be 
evaluated for their pathogenic effect in the patient. For many of the studied disease genes, up 
to 50% of point mutations within exons affect splicing, and more than half of all known 
disease-causing mutations are now estimated to disrupt splicing (Lopez-Bigas et al. 2005). 
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A GENERAL OVERVIEW ON THE PRE-mRNA SPLICING REACTION 
 
Genes are transcribed into a pre-mRNA from which intron sequences are removed and 
exons joined together to generate the mature protein-coding mRNA transcript. The chemistry 
of the splicing reaction is mediated by the spliceosome, an RNA-based machine containing 
five snRNAs and numerous associated proteins (Jurica and Moore 2003). Both the snRNA 
and protein components of the spliceosome interact with defined core splicing signal 
sequences at the exon/intron boundaries to direct intron excision and exon ligation (Wang and 
Burge 2008) (see Figure 1). At the 5’ splice site only the first two bases of the intron (GU) are 
generally conserved. The second consensus sequence at the 3’ splice site is defined by three 
separate elements: the branch site, the polypyrimidine tract, and the 3’ splice site dinucleotide 
AG. 
U1 U2AFU2
YAG GURAGU YAG GU
5’ss 3’ss
(Y)n
PPT
YNYCRAY
BPS
Exon Exon
Intron
 
Figure 1: Classical consensus sequences targeted by mutation in human disease. The 
consensus sequences define exon/intron boundaries, in particular; ss: splice site, BPS: branch 
point sequence, PPT: polypyrimidine tract, Y=U or C; R=G or A. The 5’ ss is recognized by 
the U1 snRNP, whereas U2AF and U2 snRNP recognize the 3’ss elements (adapted from 
House and Lynch 2008). 
 
Although the consensus splice sites function to direct the splicing machinery, these sequence 
elements are short so that additional sequence elements outside of the splice sites contribute to 
the control of pre-mRNA splicing. Recognition of most exons during splicing is now believed 
to be under the combinatorial control of multiple regulatory RNA elements that increase the 
overall fidelity of the splicing reaction. These elements are recognized by specific splicing 
protein factors, which then recruit spliceosomal components through protein-protein 
interactions (Smith and Valcarcel 2000; Singh and Valcarcel 2005; Hertel 2008; House and 
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Lynch 2008). Importantly, these regulatory RNA sequences are targets for pathogenic 
mutation (Pagani and Baralle 2004). 
 
 
ENHANCERS AND SILENCERS OF THE PRE-mRNA SPLICING REACTION 
Additional splicing regulatory sequences are cis-acting, can occur within either exonic 
or intronic regions and function by recruiting trans-acting splicing factors. They can either 
promote recruitment of the spliceosome and exon inclusion (splicing enhancers) or disrupt 
assembly of the splicing complex and cause exon skipping (splicing silencers) (Pagani and 
Baralle 2004). The best characterized regulatory elements, exonic splicing enhancers (ESEs), 
are usually recognized by a family of proteins known as SR proteins, which contain an RNA-
binding domain and a region rich in arginine-serine dipeptides (RS domain). It is likely that 
SR proteins are required for the correct splicing of most exons. However, regulation of pre-
mRNA splicing is much more complex than the simple ESE recruitment model. Intronic 
splicing enhancers (ISEs) and splicing silencers, either exonic (ESS) or intronic (ISS), occur 
frequently and influence splice site selection (Figure 2) (Black 2003; Pagani and Baralle 
2004). ESS- or ISS-mediated splicing repression involves their recognition by heterogeneous 
nuclear RNP (hnRNP) proteins and several mechanisms have been proposed. hnRNPs can 
oligomerize along splicing silencers and repress spliceosomal assembly (Zhu et al. 2001), or 
block the recruitment of snRNPs (Tange et al. 2001), or act by looping out exons (Martinez-
Contreras et al. 2006). ESS sequences have higher content of T (38%) and G (36%) and 
reduced levels of A (17%) and C (9%) (Wang et al. 2004), while ESEs include purine-rich 
and AC-rich elements (Graveley 2000; Zheng 2004).  
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Figure 2: Schematic representation of splicing regulation. Correct splicing depends on cis-
elements including exonic splicing enhancers (ESE) or silencers (ESS) as well as intronic 
splicing enhancers (ISE) or silencers (ISS) recognized by trans-acting splicing factors (SR 
proteins, hnRNPs, other factors). This combinatorial regulation mode is also at the origin of 
alternative splicing events naturally observed in many genes (dashed lines, with the middle 
exon either included or excluded) (adapted from Wang and Burge 2008). 
 
Typically, silencers and enhancers are present within the vicinity of potential 
exon/intron junctions, suggesting that the interplay between activating and repressing cis-
acting elements modulates the probability of exon inclusion (Hertel 2008). Current knowledge 
indicates that the recognition of a typical exon is influenced by multiple distinct cis-acting 
elements, a notion strongly supported by computational analyses (Zhang and Chasin 2004; 
Wang et al. 2004). As a consequence of this concept, the distinct cis-acting elements are 
targets for intronic or exonic point mutations that disrupt normal splicing of the affected gene. 
 
EXAMPLES OF MUTATIONS THAT DISRUPT ENHANCERS OR CREATE 
SILENCERS  
Table 1 shows representative examples from 10 human disease genes in which 
missense mutations or silent nucleotide changes were experimentally reported to interfere 
with the correct mRNA splicing. Many of these mutations were mis-classified in the past as 
missense mutations or silent variants whenever the analysis was limited to genomic sequence 
analysis alone.  
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Table 1: Examples of missense or silent mutations that cause aberrant splicing. 
Representative mutations from ten disease genes were selected and designated with regard to 
both the nucleotide in the coding sequence (c.) and the corresponding amino acid in the 
protein sequence (p.), according to the international nomenclature convention available at 
http://www.hgvs.org/mutnomen/recs-DNA.html. 
 
 
Gene Disease Mutation Exon Effect on splicing Reference 
APC 
Familial 
adenomatous 
polyposis (FAP) 
c.1918C>G, 
p.Arg640Gly 14 
Exon skipping by 
disruption of an 
ASF/SF2 ESE motif 
Gonçalves 
et al., 2009 
hMSH2 
Hereditary Non 
Polyposis 
Colorectal Cancer 
(HNPCC) 
c.806C>T, 
p.Ser268Leu 5 
Exon skipping by 
disruption of a SRp55 
ESE motif 
Lastella    
et al., 2006 
hMLH1 
Hereditary Non 
Polyposis 
Colorectal Cancer 
(HNPCC) 
c.842C>T, 
p.Ala281Val 10 
Exon skipping by 
disruption of 
ASF/SF2 and SC35 
ESE motifs 
Lastella    
et al., 2006 
BRCA1 Breast and ovarian 
cancers 
c.5242C>A, 
p.Ala1708Glu 18 
Exon skipping by 
creating an ESS for 
hnRNP A1 and H/F 
Millevoi   
et al., 2009 
NF1 Neurofibromatosis c.945G>A, p.Gln315Gln 7 
Exon skipping by 
disruption of an 
ASF/SF2 ESE motif 
Bottillo     
et al., 2007 
ATM Ataxia-telangiectasia 
c.6154G>A, 
p.Glu2032Lys 44 Exon skipping 
Teraoka    
et al., 1999 
POMGNT1 
Congenital 
muscular 
dystrophy 
c.636C>T, 
p.Asp179Val 7 
Exon skipping by 
creating an ESS for 
hnRNP H 
Oliveira    
et al., 2008 
RPGR Retinitis pigmentosa 
c.213G>A, 
p.Gly52Arg 2 Exon skipping 
Demirci    
et al., 2004 
ATP6AP2 
X-linked mental 
retardation and 
epilepsy 
c.321C>T, 
p.Asp107Asp 4 
Exon skipping by 
disruption of an ESE 
motif 
Ramser     
et al., 2005 
CFTR Cystic fibrosis c.1826A>G, p.Asp565Gly 12 
Exon skipping by 
disruption of a 
composite exonic 
regulatory element of 
splicing (CERES)  
Pagani      
et al., 2003 
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For further examples and details, the reader is referred to a number of excellent review 
articles (Cartegni et al. 2002; Faustino and Cooper 2003; Pagani and Baralle 2004; Baralle 
and Baralle 2005). 
 
 
BIOINFORMATIC TOOLS TO PREDICT THE EFFECT OF POINT MUTATIONS 
Computational methods have recently been developed to predict sequence motifs for 
enhancers and silencers, ESEs are short, frequently purine-rich sequences and are recognized 
by members of the SR protein family. Attempts to elucidate the RNA binding specificities of 
each SR protein have shown that they bind a vast array of RNA sequences which are highly 
degenerate. The factors that bind to ESS and ISS have not been characterized to a similar 
extent, however, hnRNPs have been generally implicated in interactions with these elements. 
 
Table 2: List of selected bioinformatic tools to identify splicing regulatory RNA elements  
Program URL Reference 
ESEfinder http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home Cartegni et al., 2003 
PESX: Putative 
Exonic Splicing 
Enhancers/Silencers 
http://cubweb.biology.columbia.edu/pesx/ 
Zhang and Chasin, 
2004; Zhang et al., 
2005 
ESR search http://ast.bioinfo.tau.ac.il/ESR.htm Goren et al., 2006 
Splicing Rainbow http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8 Stamm et al., 2006 
Human Splicing 
Finder http://www.umd.be/HSF/ Desmet et al., 2009 
 
Using these software tools, normal and mutant sequences can be submitted and the 
differences in splicing factor binding predicted. Unfortunately, enhancers and silencers lack a 
well defined consensus sequence, are not always unequivocally defined and may overlap in 
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their functions. This currently precludes a reliable prediction of the effect of a genomic 
mutation on the splicing process (Baralle and Baralle 2005; Houdayer et al. 2008; Gonçalves 
et al. 2009). 
 
 
EXPERIMENTAL CONFIRMATION OF THE MUTATION EFFECT ON SPLICING  
Although a variety of bioinformatic tools have been developed in recent years that 
predict splicing regulatory elements, they are at present insufficient to decide whether a 
genomic point mutation affects splicing. For this, experimental confirmation is still required, 
as detailed in the following.  
Whether a suspected disease-causing mutation affects splicing should ideally be determined 
in RNA from the affected tissue because cis-acting splicing mutations can have tissue-specific 
effects. Unfortunately, the appropriate tissues are often not available. Frequently, the study of 
RNA extracted from peripheral blood lymphocytes of individual patients is sufficient to 
confirm splicing defects. In this case, the transcript pattern in RNA samples from patient and 
healthy controls should be compared. For example, a novel missense mutation in exon 14 of 
the APC gene was identified in a patient with familial adenomatous polyposis syndrome 
(FAP) (Gonçalves et al. 2009). To characterize whether the resulting p.Arg640Gly mutation 
could affect splicing of the APC transcript, RNA was isolated from the proband or from 
healthy individuals. The APC transcript between exons 13 and 15 was amplified by RT-PCR 
and the obtained product bands were isolated by agarose gel electrophoresis and sequenced. 
All healthy individuals were found to express the expected wild-type product containing 
exons 13, 14 and 15. In the patient, however, a second transcript lacking exon 14 became the 
predominant product. Densitometric estimation of the band intensities revealed that in normal 
individuals the full length APC transcript accounted for roughly 85% whereas in the patient, 
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the expression of this product dropped to 40%. These experimental data demonstrated a 
splicing defect in the patient (see Figure 3). 
600
1000
N1 PM N2
ex (13+15)
ex (13+14+15)
 
 
Figure 3: Skipping of exon 14 in the patient with APC mutation p.Arg640Gly. RT-PCR 
analysis of APC expression in peripheral blood lymphocytes isolated from the patient (P) or 
two healthy individuals (N1, N2). APC transcripts were amplified between exons 13 and 15 
and the identity of the indicated bands verified by direct sequencing (the third unlabelled band 
corresponds to a heteroduplex product formed under non-denaturing gel conditions; (M) = 
100 base pair molecular weight marker). 
 
In other cases, the necessary samples may be difficult to obtain or the gene of interest is not 
expressed in lymphocytes. An alternative measure to demonstrate that a missense mutation 
affects the splicing fidelity is their subcloning into minigenes that serve as splicing reporters 
(Cooper 2005; Baralle and Baralle 2005). In order to determine whether the above mentioned 
APC p.Arg640Gly point mutation was sufficient to cause the observed exon skipping, such a 
splicing reporter vector was constructed (see Figure 4). The wild type and mutant exon 14 
sequences were amplified from normal or patient genomic DNA together with flanking intron 
sequences of 118 bp upstream and 245 bp downstream. Both fragments were cloned between 
constitutively spliced exons of the chimeric pTB reporter, as previously published (Pagani et 
al. 2003).  
Following transfection into appropriate cells (in this case colorectal cell lines), the minigenes 
are transcribed and spliced in vivo. Then the mRNA derived from the hybrid minigene can be 
analysed using reverse transcriptase PCR (RT-PCR) with primers that amplify specifically the 
minigene-derived products. Finally, the spliced products are visualised on an agarose gel. 
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This analysis demonstrated that the APC missense mutation p.Arg640Gly is sufficient to 
cause exon 14 skipping. 
α 2-3 globin BRA2
Nde I
pTB minigene
A
B
Nde I Nde I
Intron 13 Intron 14
Exon 14118 bp
215 bp
245 bp
Wildtype: --TATTACGGAAT--
Mutant: --TATTAGGGAAT--
c.1918C>G = p.Arg640Gly
M pTB
pTB-
ex14 C>G
pTB-
ex14 wt
300 
200 
400 
500 
bp
452 bp
237 bp
Exon 14
 
Figure 4: Splicing minigene reporter assay to confirm the effect of APC mutation 
p.Arg640Gly. (A) Schematic representation of the pTB reporter minigene used (Pagani et al. 
2003) and the subcloning of a genomic APC fragment isolated from either wild type or 
mutant alleles. (B). RT-PCR analysis with primers ‘α2-3 globin’ and ‘BRA2’ of the 
transcripts derived from the indicated reporter minigenes following their expression in 
colorectal DLD-1 cells. Note that exon 14 is completely skipped in the pTB reporter 
containing the p.Arg640Gly (c.1918C>G) mutation (pTB-ex14 C>G), whereas exon 14 is 
included in the construct containing the wild type sequence (pTB-ex 14 wt).  
 
 
Such minigene reporter assays not only help to clarify the mutation effect but also 
represent an important opportunity to validate bioinformatic prediction tools and clarify the 
basic molecular mechanisms that underlie the pre-mRNA splicing process. For example, in 
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the above example of APC exon 14, the mutant sequence was examined with several 
bioinformatic search tools, which predicted loss of recognition motifs for SRp55 and for 
ASF/SF2, or the creation of a splicing silencing hnRNP A1 motif. Upon further experimental 
analysis only ASF/SF2 showed convincing evidence for a role in this splicing event. 
 
 
CONCLUSION 
The pathogenic effect of missense mutations or silent nucleotide substitutions, which 
are encountered during genetic testing in human disease genes, is frequently due to 
interference with essential splicing regulatory RNA elements. Because bioinformatic 
prediction is currently insufficient, the pathogenic potential of missense mutations can only be 
decided upon experimental analysis of the splicing pattern in either patient RNA or reporter 
minigenes.  
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